WallStreetZenWallStreetZen

NYSE: BMY
Bristol Myers Squibb Co Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BMY

Based on 9 analysts offering 12 month price targets for Bristol Myers Squibb Co

Min Forecast
$34.00-27.44%
Avg Forecast
$56.00+19.5%
Max Forecast
$68.00+45.11%

Should I buy or sell BMY stock?

Based on 9 analysts offering ratings for Bristol Myers Squibb Co.

Hold
Strong Buy
2 analysts 22.22%
Buy
0 analysts 0%
Hold
6 analysts 66.67%
Sell
0 analysts 0%
Strong Sell
1 analysts 11.11%

Be the first to know when Wall Street analysts revise their BMY stock forecasts and price targets.

BMY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-07-10
lockedlocked$00.00+00.00%2025-04-28
lockedlocked$00.00+00.00%2025-04-23
lockedlocked$00.00+00.00%2025-04-23
lockedlocked$00.00+00.00%2025-04-22
UBS
Top 13%
88
HoldMaintains$54.00+15.24%2025-04-11
Goldman Sachs
Bottom 45%
45
HoldDowngrades$55.00+17.37%2025-04-08
Cantor Fitzgerald
Top 31%
70
HoldMaintains$55.00+17.37%2025-02-04
Citigroup
Top 19%
82
HoldMaintains$65.00+38.71%2025-01-28

1 of 1

Forecast return on equity

Is BMY forecast to generate an efficient return?

Company
64.87%
Industry
355.95%
Market
89.88%
BMY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BMY forecast to generate an efficient return on assets?

Company
12.2%
Industry
25.06%
BMY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BMY earnings per share forecast

What is BMY's earnings per share in the next 3 years based on estimates from 14 analysts?

Avg 1 year Forecast
$6.66+148.37%
Avg 2 year Forecast
$6.03+124.86%
Avg 3 year Forecast
$5.87+119.05%
BMY's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

BMY revenue forecast

What is BMY's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$46.3B-2.9%
Avg 2 year Forecast
$42.8B-10.07%
Avg 3 year Forecast
$42.3B-11.24%
BMY's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BMY earnings growth forecast

How is BMY forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
29.14%
Industry
35.79%
Market
15.82%
BMY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
BMY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
BMY's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

BMY revenue growth forecast

How is BMY forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
-4.26%
Industry
7.27%
Market
10.4%
BMY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BMY's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BMY vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
BMY$46.86$56.00+19.50%Hold
GSK$38.28N/AN/A
SNY$48.61$65.00+33.72%Hold
GILD$109.64$118.00+7.62%Strong Buy
PFE$25.65$27.33+6.56%Hold
View Top General Drug Manufacturer Stocks

Bristol Myers Squibb Co Stock Forecast FAQ

Is Bristol Myers Squibb Co Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 9 Wall Street analysts covering (NYSE: BMY) stock is to Hold BMY stock.

Out of 9 analysts, 2 (22.22%) are recommending BMY as a Strong Buy, 0 (0%) are recommending BMY as a Buy, 6 (66.67%) are recommending BMY as a Hold, 0 (0%) are recommending BMY as a Sell, and 1 (11.11%) are recommending BMY as a Strong Sell.

If you're new to stock investing, here's how to buy Bristol Myers Squibb Co stock.

What is BMY's earnings growth forecast for 2025-2027?

(NYSE: BMY) Bristol Myers Squibb Co's forecast annual earnings growth rate of 29.14% is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 35.79%, and while it is forecast to beat the US market's average forecast earnings growth rate of 15.82%.

Bristol Myers Squibb Co's earnings in 2025 is $5,419,000,000.On average, 14 Wall Street analysts forecast BMY's earnings for 2025 to be $13,545,904,888, with the lowest BMY earnings forecast at $12,495,396,173, and the highest BMY earnings forecast at $14,245,565,670. On average, 13 Wall Street analysts forecast BMY's earnings for 2026 to be $12,264,007,485, with the lowest BMY earnings forecast at $9,890,492,737, and the highest BMY earnings forecast at $13,411,182,538.

In 2027, BMY is forecast to generate $11,947,145,403 in earnings, with the lowest earnings forecast at $9,992,246,777 and the highest earnings forecast at $13,024,517,184.

What is BMY's revenue growth forecast for 2025-2027?

(NYSE: BMY) Bristol Myers Squibb Co's forecast annual revenue growth rate of -4.26% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.27%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.

Bristol Myers Squibb Co's revenue in 2025 is $47,636,000,000.On average, 10 Wall Street analysts forecast BMY's revenue for 2025 to be $94,130,696,978,488, with the lowest BMY revenue forecast at $93,212,806,340,430, and the highest BMY revenue forecast at $94,768,991,934,221. On average, 10 Wall Street analysts forecast BMY's revenue for 2026 to be $87,177,230,831,799, with the lowest BMY revenue forecast at $83,073,457,817,141, and the highest BMY revenue forecast at $90,896,884,378,650.

In 2027, BMY is forecast to generate $86,043,644,013,770 in revenue, with the lowest revenue forecast at $82,228,115,774,879 and the highest revenue forecast at $90,583,481,933,910.

What is BMY's forecast return on assets (ROA) for 2025-2028?

(NYSE: BMY) forecast ROA is 12.2%, which is lower than the forecast US Drug Manufacturers - General industry average of 25.06%.

What is BMY's Price Target?

According to 9 Wall Street analysts that have issued a 1 year BMY price target, the average BMY price target is $56.00, with the highest BMY stock price forecast at $68.00 and the lowest BMY stock price forecast at $34.00.

On average, Wall Street analysts predict that Bristol Myers Squibb Co's share price could reach $56.00 by Jul 10, 2026. The average Bristol Myers Squibb Co stock price prediction forecasts a potential upside of 19.5% from the current BMY share price of $46.86.

What is BMY's Earnings Per Share (EPS) forecast for 2025-2027?

(NYSE: BMY) Bristol Myers Squibb Co's current Earnings Per Share (EPS) is $2.68. On average, analysts forecast that BMY's EPS will be $6.66 for 2025, with the lowest EPS forecast at $6.14, and the highest EPS forecast at $7.00. On average, analysts forecast that BMY's EPS will be $6.03 for 2026, with the lowest EPS forecast at $4.86, and the highest EPS forecast at $6.59. In 2027, BMY's EPS is forecast to hit $5.87 (min: $4.91, max: $6.40).

What is BMY's forecast return on equity (ROE) for 2025-2028?

(NYSE: BMY) forecast ROE is 64.87%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.